Zevra Therapeutics, Inc.
ZVRA
$12.28
-$0.40-3.12%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 119.40% | 201.29% | 350.91% | 244.60% | 161.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 119.40% | 201.29% | 350.91% | 244.60% | 161.81% |
| Cost of Revenue | -64.47% | 98.37% | 122.22% | 124.35% | 239.77% |
| Gross Profit | 191.06% | 228.91% | 455.65% | 295.44% | 140.32% |
| SG&A Expenses | 2.77% | 22.34% | 41.50% | 35.56% | 66.06% |
| Depreciation & Amortization | -80.24% | -59.46% | -38.06% | -4.25% | 66.20% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.77% | -0.12% | 0.08% | 1.91% | 24.31% |
| Operating Income | 164.67% | 113.86% | 95.13% | 66.61% | 19.24% |
| Income Before Tax | 223.83% | 277.00% | 196.16% | 159.83% | 132.11% |
| Income Tax Expenses | -41.21% | -44.77% | -77.56% | -- | 10,494.35% |
| Earnings from Continuing Operations | 2,103.59% | 235.04% | 178.88% | 139.40% | 103.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2,103.59% | 235.04% | 178.88% | 139.40% | 103.96% |
| EBIT | 164.67% | 113.86% | 95.13% | 66.61% | 19.24% |
| EBITDA | 175.31% | 119.47% | 99.78% | 70.91% | 23.97% |
| EPS Basic | 632.19% | 208.72% | 161.80% | 124.21% | 89.26% |
| Normalized Basic EPS | 137.17% | 103.07% | 96.77% | 68.08% | 20.39% |
| EPS Diluted | 533.36% | 204.80% | 159.55% | 122.60% | 87.37% |
| Normalized Diluted EPS | 135.93% | 102.78% | 96.64% | 68.38% | 20.77% |
| Average Basic Shares Outstanding | 9.40% | 14.32% | 19.61% | 28.26% | 33.76% |
| Average Diluted Shares Outstanding | 11.58% | 17.20% | 21.69% | 29.17% | 34.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |